Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Public ClinicalTrials.gov record NCT05925803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Study identification
- NCT ID
- NCT05925803
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 314 participants
Conditions and interventions
Conditions
Interventions
- Anifrolumab (blinded) Combination Product
- Placebo (blinded) Drug
- Anifrolumab (unblinded, open label) Combination Product
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2023
- Primary completion
- Jan 5, 2027
- Completion
- Apr 4, 2028
- Last update posted
- Aug 23, 2026
2023 – 2028
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Chula Vista | California | 91910 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | New Haven | Connecticut | 06519 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Boca Raton | Florida | 33486 | — |
| Research Site | Fort Lauderdale | Florida | 33309 | — |
| Research Site | Gainesville | Florida | 32603 | — |
| Research Site | Jacksonville | Florida | 32216 | — |
| Research Site | Margate | Florida | 33063 | — |
| Research Site | South Miami | Florida | 33143 | — |
| Research Site | Tamarac | Florida | 33321 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | New Orleans | Louisiana | 70121 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Babylon | New York | 11702 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Allen | Texas | 75013 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 124 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05925803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05925803 live on ClinicalTrials.gov.